220 related articles for article (PubMed ID: 27865001)
1. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.
Ominsky MS; Boyd SK; Varela A; Jolette J; Felx M; Doyle N; Mellal N; Smith SY; Locher K; Buntich S; Pyrah I; Boyce RW
J Bone Miner Res; 2017 Apr; 32(4):788-801. PubMed ID: 27865001
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
3. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
[TBL] [Abstract][Full Text] [Related]
4. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
[TBL] [Abstract][Full Text] [Related]
5. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.
Ominsky MS; Libanati C; Niu QT; Boyce RW; Kostenuik PJ; Wagman RB; Baron R; Dempster DW
J Bone Miner Res; 2015 Jul; 30(7):1280-9. PubMed ID: 25684625
[TBL] [Abstract][Full Text] [Related]
6. Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys.
Boyce RW; Niu QT; Ominsky MS
Bone; 2017 Aug; 101():77-87. PubMed ID: 28428078
[TBL] [Abstract][Full Text] [Related]
7. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Nakanishi Y; Tanaka M; Bruce M; Deacon S; Kawabata K
Bone; 2016 May; 86():43-52. PubMed ID: 26921823
[TBL] [Abstract][Full Text] [Related]
8. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.
Fox J; Miller MA; Newman MK; Recker RR; Turner CH; Smith SY
Bone; 2007 Sep; 41(3):321-30. PubMed ID: 17573250
[TBL] [Abstract][Full Text] [Related]
9. Minodronic acid ameliorates vertebral bone strength by increasing bone mineral density in 9-month treatment of ovariectomized cynomolgus monkeys.
Tanaka M; Mori H; Kawabata K; Mashiba T
Bone; 2016 Jul; 88():157-164. PubMed ID: 27155564
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.
Sato M; Westmore M; Ma YL; Schmidt A; Zeng QQ; Glass EV; Vahle J; Brommage R; Jerome CP; Turner CH
J Bone Miner Res; 2004 Apr; 19(4):623-9. PubMed ID: 15005850
[TBL] [Abstract][Full Text] [Related]
11. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Jerome CP; Burr DB; Van Bibber T; Hock JM; Brommage R
Bone; 2001 Feb; 28(2):150-9. PubMed ID: 11182372
[TBL] [Abstract][Full Text] [Related]
12. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.
Cusick T; Chen CM; Pennypacker BL; Pickarski M; Kimmel DB; Scott BB; Duong LT
J Bone Miner Res; 2012 Mar; 27(3):524-37. PubMed ID: 22113921
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Jerome CP; Johnson CS; Vafai HT; Kaplan KC; Bailey J; Capwell B; Fraser F; Hansen L; Ramsay H; Shadoan M; Lees CJ; Thomsen JS; Mosekilde L
Bone; 1999 Sep; 25(3):301-9. PubMed ID: 10495134
[TBL] [Abstract][Full Text] [Related]
14. Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate.
Itoh F; Kojima M; Furihata-Komatsu H; Aoyagi S; Kusama H; Komatsu H; Nakamura T
J Bone Miner Res; 2002 Mar; 17(3):534-43. PubMed ID: 11874245
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
16. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
17. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
18. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
[TBL] [Abstract][Full Text] [Related]
19. Long-term changes in bone mineral and biomechanical properties of vertebrae and femur in aging, dietary calcium restricted, and/or estrogen-deprived/-replaced rats.
Jiang Y; Zhao J; Genant HK; Dequeker J; Geusens P
J Bone Miner Res; 1997 May; 12(5):820-31. PubMed ID: 9144349
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
